State your position on sponsored CME

Should the era of pharma-sponsored CME draw to a close? Or is industry-funded medical education an essential cog in the healthcare machine? Weigh in with your opinion at the Pharma Marketing Blog. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.